Drug: Palbociclib (Ibrance, Pfizer)
Status: The therapy was approved in combination with fulvestrant (Faslodex, AstraZeneca) for the treatment of women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.
Significant Trial Data:
· Five hundred twenty-one pre- and postmenopausal women were randomly assigned (2-1) to receive palbociclib plus fulvestrant or placebo plus